Camilla F. Andersen

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Care and Outcomes of New-Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022.

Care and Outcomes of New-Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022.

Journal: Journal of the American Heart Association

Published: April 09, 2026

The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial.

The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial.

Journal: Cardiovascular diabetology

Published: February 24, 2026

Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial.

Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial.

Journal: American heart journal

Published: October 09, 2025

The Effect of Empagliflozin on Left Ventricular Mass and Volumes in Older Adult Individuals With Overweight and High Risk of Heart Failure: The Empire Prevent Cardiac Trial.

The Effect of Empagliflozin on Left Ventricular Mass and Volumes in Older Adult Individuals With Overweight and High Risk of Heart Failure: The Empire Prevent Cardiac Trial.

Journal: Journal of cardiac failure

Published: September 26, 2025

Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic Trial.

Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic Trial.

Journal: European journal of preventive cardiology

Published: August 26, 2025

Associations of body mass index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study (a NorthStar substudy).

Associations of body mass index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study (a NorthStar substudy).

Journal: Cardiovascular diabetology

Published: August 24, 2025

Care and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003-22: a nationwide registry-based cohort study.

Care and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003-22: a nationwide registry-based cohort study.

Journal: The Lancet regional health. Europe

Published: June 20, 2025

Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study.

Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study.

Journal: Cardiovascular diabetology

Published: May 22, 2025

Albuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes.

Albuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes.

Journal: JACC. Advances

Published: March 05, 2025

Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score.

Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score.

Journal: Journal of the American Heart Association

Published: February 03, 2025

Temporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: a nationwide study from 1997 to 2018 on 152 059 patients.

Temporal trends in mortality, heart failure hospitalization, and stroke in heart failure patients with and without atrial fibrillation: a nationwide study from 1997 to 2018 on 152 059 patients.

Journal: European heart journal. Quality of care & clinical outcomes

Published: May 21, 2024

Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial).

Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial).

Journal: International journal of cardiology. Heart & vasculature

Published: March 24, 2024

Showing 1-12 of 30

Last Updated: 09/26/2026